Treatment progress of non-small cell lung cancer with RET gene fusion / 肿瘤研究与临床
Cancer Research and Clinic
; (6): 547-550, 2022.
Article
in Zh
| WPRIM
| ID: wpr-958889
Responsible library:
WPRO
ABSTRACT
Non-small cell lung cancer (NSCLC) is a malignant tumor with rapid progress and high malignancy, accounting for 85% of all lung cancers. Treatment has shifted from traditional surgery, radiotherapy and chemotherapy to targeted therapy. Targeted therapy can prolong the survival of patients with positive driver gene fusion. With the continuous progress of biological research, targets related to NSCLC have gradually been discovered. Among the many driving genes of NSCLC, RET fusion is an important emerging target discovered in recent years. It has been confirmed to have a high incidence in non-smoking, young and low-differentiated NSCLC patients. This article reviews RET gene fusion in NSCLC, the relationship between the two and the treatment progress.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Cancer Research and Clinic
Year:
2022
Type:
Article